Sarepta Therapeutics (NASDAQ:SRPT) Given “Underweight” Rating at Barclays

Barclays reissued their underweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday.

A number of other research firms also recently commented on SRPT. Baird R W downgraded Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Cantor Fitzgerald reissued a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Leerink Partners reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Wells Fargo & Company dropped their target price on shares of Sarepta Therapeutics from $65.00 to $48.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Seven research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus target price of $51.42.

Sarepta Therapeutics Stock Up 16.2%

SRPT stock opened at $13.86 on Monday. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The firm has a 50 day simple moving average of $25.64 and a 200-day simple moving average of $62.85. The company has a market capitalization of $1.36 billion, a P/E ratio of -5.15 and a beta of 0.45. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company’s revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. On average, equities research analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the company. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics during the first quarter valued at $31,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sarepta Therapeutics during the 1st quarter worth about $44,000. Finally, Pandora Wealth Inc. purchased a new position in Sarepta Therapeutics during the 1st quarter valued at about $45,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.